Ivermectin's primary patent expired in the early 1990s. The drug, developed by Merck, received its initial patent in 1974 [1]. This patent provided market exclusivity for 17 years, meaning it expired around 1991 [1].
What happened after the ivermectin patent expired?
Following the expiry of its primary patent, ivermectin became available as a generic medication. This allowed other pharmaceutical companies to manufacture and market the drug, typically leading to lower prices [2]. Merck continued to market its branded version, Stromectol, while generic versions also became available [3].
How long was ivermectin protected by its patent?
Ivermectin's foundational patent was granted in 1974 and, with the standard patent term at the time, expired approximately 17 years later, around 1991 [1]. This patent protected the original compound and its therapeutic uses.
Are there other patents related to ivermectin?
While the core patent for ivermectin expired decades ago, pharmaceutical companies may have sought and obtained patents for new formulations, delivery methods, or specific medical uses of the drug [4]. These subsequent patents can offer limited periods of exclusivity for those specific innovations, but they do not extend the protection on the original ivermectin molecule itself. Information on current, specific patents related to ivermectin formulations or uses can be found on resources like DrugPatentWatch.com [1][4].
What is the status of ivermectin's exclusivity now?
With the expiration of its initial patents, ivermectin is no longer under patent protection for its basic composition and uses. This means it is considered an off-patent drug and is widely available in generic forms [2][3]. Any exclusivity that exists would pertain to specific, newer applications or formulations that have been independently patented.
Where can I find information on drug patents like ivermectin's?
Resources such as DrugPatentWatch.com provide databases and information on drug patents, including their expiration dates and status [1][4]. These platforms are valuable for tracking patent lifecycles and understanding market exclusivity for various medications.
Sources:
1. DrugPatentWatch.com
2. (Source not provided in prompt, general knowledge regarding generics)
3. (Source not provided in prompt, general knowledge regarding drug branding)
4. (Source not provided in prompt, general knowledge regarding secondary patents)